Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00769041 · ClinicalTrials.gov registry record · Phase 1
A Thorough EKG Safety Study of TA-1790 (Avanafil)
A Phase 1 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT00769041 is a Phase 1 study that has completed, run by VIVUS. The registered enrollment target is 57 participants.
The verdict
NCT00769041, a Phase 1 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
This study is to assess whether treatment with a therapeutic (100 mg) or supratherapeutic (800 mg) dose of avanafil has the potential to cause QT/QTc prolongation in healthy volunteers.
Interventions
- DRUG moxifloxacin
- DRUG sugar pill
- DRUG avanafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00769041
The ClinicalTrials.gov registry entry for NCT00769041 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which moxifloxacin is the first listed.
NCT00769041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00769041 about?
NCT00769041 is a clinical study titled "A Thorough EKG Safety Study of TA-1790 (Avanafil)". This study is to assess whether treatment with a therapeutic (100 mg) or supratherapeutic (800 mg) dose of avanafil has the potential to cause QT/QTc prolongation in healthy volunteers.
What is the current status of trial NCT00769041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2008-10. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00769041?
The interventions under investigation include: moxifloxacin (DRUG), sugar pill (DRUG), avanafil (DRUG).
Who is sponsoring clinical trial NCT00769041?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.